Efficacy and safety of sacubitril/valsartan in heart failure compared to renin-angiotensin-aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials.

Publication Year: 2023

DOI:
10.5114/aoms/159113

PMCID:
PMC10259398

PMID:
37313196

Journal Information

Full Title: Arch Med Sci

Abbreviation: Arch Med Sci

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine, General & Internal

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest M.B. has received research grants/support from Amgen, Mylan/Viatris, Sanofi, and Valeant, and he has served as a consultant/received speakers fee from Amgen, Daiichi-Sankyo, Esperion, Freia Pharmaceuticals, Herbapol, Kogen, KRKA, Mylan/Viatris, Novartis, Novo-Nordisk, Polfarmex, Polpharma, Sanofi-Aventis, Servier, Teva, and Zentiva. He is CMO at the Nomi Biotech Corporation Ltd. A.M.B.-D. has given lectures that were sponsored by Novartis Polska Sp.z o. o. The remaining authors do not have any competing interests to disclose."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025